Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333819 | 1.00 | REN (0.54) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL671194 | 0.98 | REN (0.55) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL4207867 | 0.93 | HDAC1 (0.57) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21628078 | 0.93 | REN (0.56) | RENHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL7778139 | 0.86 | FOLH1 (0.54) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL15796347 | 0.86 | MEN1 (0.51) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL26985651 | 0.86 | ALOX5 (0.51) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL26985914 | 0.86 | ALOX5 (0.50) | HDAC1HDAC6HDAC3HDAC2HDAC8 | |
| SCHEMBL766565 | 0.85 | L3MBTL1 (0.58) | RENHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL8325252 | 0.85 | HDAC1 (0.46) | RENHDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3501546-A2 | CYSTEINE DRUG CONJUGATES AND USE OF SAME | Seattle Genetics, Inc. (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2790731-A2 | FGFR-BINDER-ACTIVE AGENT CONJUGATES | Seattle Genetics, Inc. (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| EP-2699268-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | Seattle Genetics, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013087716-A2 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2012143499-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143497-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | REN 678/4885HDAC1 3194/4885HDAC6 1367/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | REN 678/4885HDAC1 3194/4885HDAC6 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.